UAE Pharmacovigilance Market Size & Outlook, 2023-2030

The pharmacovigilance market in the UAE is expected to reach a projected revenue of US$ 17.0 million by 2030. A compound annual growth rate of 6.6% is expected of the UAE pharmacovigilance market from 2024 to 2030.
Revenue, 2023 (US$M)
$10.8
Forecast, 2030 (US$M)
$17.0
CAGR, 2024 - 2030
6.7%
Report Coverage
UAE

UAE pharmacovigilance market highlights

  • The UAE pharmacovigilance market generated a revenue of USD 10.8 million in 2023 and is expected to reach USD 17.0 million by 2030.
  • The UAE market is expected to grow at a CAGR of 6.6% from 2024 to 2030.
  • In terms of segment, phase 4 was the largest revenue generating product life cycle in 2023.
  • Phase 1 is the most lucrative product life cycle segment registering the fastest growth during the forecast period.


Pharmacovigilance market data book summary

Market revenue in 2023USD 10.8 million
Market revenue in 2030USD 17.0 million
Growth rate6.6% (CAGR from 2023 to 2030)
Largest segmentPhase 4
Fastest growing segmentPhase 1
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPre Clinical, Phase 1, Phase 2, Phase 3, Phase 4
Key market players worldwideAccenture PLC Class A, IQVIA Holdings Inc, Cognizant Technology Solutions Corp Class A, Linical Americas, International Business Machines Corp, Labcorp Holdings Inc, ArisGlobal, Capgemini SE, ITClinical, Icon PLC, TAKE Solutions, PAREXEL, Wipro Ltd ADR, United Biosource Corporation, FMD K&L, BioClinica


Other key industry trends

  • In terms of revenue, UAE accounted for 0.1% of the global pharmacovigilance market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Middle East & Africa, South Africa pharmacovigilance market is projected to lead the regional market in terms of revenue in 2030.
  • Saudi Arabia is the fastest growing regional market in Middle East & Africa and is projected to reach USD 49.0 million by 2030.

Phase 4 was the largest segment with a revenue share of 75.93% in 2023. Horizon Databook has segmented the UAE pharmacovigilance market based on pre clinical, phase 1, phase 2, phase 3, phase 4 covering the revenue growth of each sub-segment from 2018 to 2030.


The increasing number of ADR reports, coupled with rising investment of government for the development of healthcare infrastructure in the country, is driving the market. Moreover, rising awareness regarding the adoption of PV services, along with the availability of PV platforms, which allow ease in reporting ADR, is anticipated to fuel the market growth.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Pharmacovigilance Market Companies

Name Profile # Employees HQ Website

UAE pharmacovigilance market size, by product life cycle, 2018-2030 (US$M)

UAE Pharmacovigilance Market Outlook Share, 2023 & 2030 (US$M)

UAE pharmacovigilance market size, by product life cycle, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more